MBX Awaits Value-Creating Milestones, With Phase II Hypoparathyroidism Data Due Any Day

Founders Are Pharma Veterans, Repeat Entrepreneurs

 
• By Mandy Jackson
  
MBX has three peptide therapeutics from its PEP platform in or entering the clinic (Shutterstock)

More from Strategy

More from Business